vs
Apellis Pharmaceuticals, Inc.（APLS）与GRAFTECH INTERNATIONAL LTD（EAF）财务数据对比。点击上方公司名可切换其他公司
Apellis Pharmaceuticals, Inc.的季度营收约是GRAFTECH INTERNATIONAL LTD的1.6倍（$199.9M vs $125.1M），Apellis Pharmaceuticals, Inc.净利率更高（-29.5% vs -34.6%，领先5.1%），GRAFTECH INTERNATIONAL LTD同比增速更快（11.9% vs -5.9%），Apellis Pharmaceuticals, Inc.自由现金流更多（$-14.3M vs $-27.1M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -4.6%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
格瑞泰克国际有限公司是石墨电极与石油焦生产商，其产品是电弧炉炼钢及其他金属生产的核心原材料。公司总部位于俄亥俄州布鲁克林海茨，在法国加来、西班牙潘普洛纳、墨西哥蒙特雷以及美国宾夕法尼亚州圣玛丽斯均设有生产基地。
APLS vs EAF — 直观对比
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $125.1M |
| 净利润 | $-59.0M | $-43.3M |
| 毛利率 | — | -7.8% |
| 营业利润率 | -25.6% | — |
| 净利率 | -29.5% | -34.6% |
| 营收同比 | -5.9% | 11.9% |
| 净利润同比 | -62.2% | -10.0% |
| 每股收益（稀释后） | $-0.40 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q1 26 | — | $125.1M | ||
| Q4 25 | $199.9M | $116.5M | ||
| Q3 25 | $458.6M | $144.0M | ||
| Q2 25 | $178.5M | $131.8M | ||
| Q1 25 | $166.8M | $111.8M | ||
| Q4 24 | $212.5M | $134.2M | ||
| Q3 24 | $196.8M | $130.7M | ||
| Q2 24 | $199.7M | $137.3M |
| Q1 26 | — | $-43.3M | ||
| Q4 25 | $-59.0M | $-65.1M | ||
| Q3 25 | $215.7M | $-28.5M | ||
| Q2 25 | $-42.2M | $-86.9M | ||
| Q1 25 | $-92.2M | $-39.4M | ||
| Q4 24 | $-36.4M | $-49.5M | ||
| Q3 24 | $-57.4M | $-36.1M | ||
| Q2 24 | $-37.7M | $-14.8M |
| Q1 26 | — | -7.8% | ||
| Q4 25 | — | -20.9% | ||
| Q3 25 | — | 7.2% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | -1.5% | ||
| Q4 24 | — | -7.8% | ||
| Q3 24 | — | -9.2% | ||
| Q2 24 | — | 2.9% |
| Q1 26 | — | — | ||
| Q4 25 | -25.6% | -33.6% | ||
| Q3 25 | 48.7% | -3.6% | ||
| Q2 25 | -18.6% | -11.0% | ||
| Q1 25 | -50.0% | -16.3% | ||
| Q4 24 | -12.3% | -18.6% | ||
| Q3 24 | -24.0% | -20.1% | ||
| Q2 24 | -14.7% | -2.0% |
| Q1 26 | — | -34.6% | ||
| Q4 25 | -29.5% | -55.9% | ||
| Q3 25 | 47.0% | -19.8% | ||
| Q2 25 | -23.6% | -65.9% | ||
| Q1 25 | -55.3% | -35.2% | ||
| Q4 24 | -17.1% | -36.9% | ||
| Q3 24 | -29.2% | -27.6% | ||
| Q2 24 | -18.9% | -10.7% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.40 | $-6.86 | ||
| Q3 25 | $1.67 | $-1.10 | ||
| Q2 25 | $-0.33 | $-0.34 | ||
| Q1 25 | $-0.74 | $-0.15 | ||
| Q4 24 | $-0.30 | $-3.51 | ||
| Q3 24 | $-0.46 | $-1.40 | ||
| Q2 24 | $-0.30 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $120.2M |
| 总债务越低越好 | — | $1.1B |
| 股东权益账面价值 | $370.1M | — |
| 总资产 | $1.1B | $997.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q1 26 | — | $120.2M | ||
| Q4 25 | $466.2M | — | ||
| Q3 25 | $479.2M | — | ||
| Q2 25 | $370.0M | — | ||
| Q1 25 | $358.4M | — | ||
| Q4 24 | $411.3M | — | ||
| Q3 24 | $396.9M | — | ||
| Q2 24 | $360.1M | $120.7M |
| Q1 26 | — | $1.1B | ||
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $929.5M | ||
| Q2 24 | — | $928.2M |
| Q1 26 | — | — | ||
| Q4 25 | $370.1M | $-259.6M | ||
| Q3 25 | $401.2M | $-194.4M | ||
| Q2 25 | $156.3M | $-168.4M | ||
| Q1 25 | $164.2M | $-105.3M | ||
| Q4 24 | $228.5M | $-78.9M | ||
| Q3 24 | $237.1M | $-9.0M | ||
| Q2 24 | $264.3M | $16.2M |
| Q1 26 | — | $997.2M | ||
| Q4 25 | $1.1B | $1.0B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $821.4M | $1.1B | ||
| Q1 25 | $807.3M | $1.2B | ||
| Q4 24 | $885.1M | $1.2B | ||
| Q3 24 | $901.9M | $1.1B | ||
| Q2 24 | $904.5M | $1.2B |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 57.16× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | $-14.9M |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-27.1M |
| 自由现金流率自由现金流/营收 | -7.1% | -21.6% |
| 资本支出强度资本支出/营收 | 0.1% | 9.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $-105.1M |
8季度趋势，按日历期对齐
| Q1 26 | — | $-14.9M | ||
| Q4 25 | $-14.2M | $-20.9M | ||
| Q3 25 | $108.5M | $24.7M | ||
| Q2 25 | $4.4M | $-53.2M | ||
| Q1 25 | $-53.4M | $-32.2M | ||
| Q4 24 | $19.4M | $-26.4M | ||
| Q3 24 | $34.1M | $23.7M | ||
| Q2 24 | $-8.3M | $-36.9M |
| Q1 26 | — | $-27.1M | ||
| Q4 25 | $-14.3M | $-39.3M | ||
| Q3 25 | $108.3M | $18.4M | ||
| Q2 25 | $4.4M | $-57.1M | ||
| Q1 25 | $-53.4M | $-42.5M | ||
| Q4 24 | $19.3M | $-39.2M | ||
| Q3 24 | — | $19.7M | ||
| Q2 24 | $-8.4M | $-43.8M |
| Q1 26 | — | -21.6% | ||
| Q4 25 | -7.1% | -33.7% | ||
| Q3 25 | 23.6% | 12.8% | ||
| Q2 25 | 2.5% | -43.3% | ||
| Q1 25 | -32.0% | -38.0% | ||
| Q4 24 | 9.1% | -29.2% | ||
| Q3 24 | — | 15.1% | ||
| Q2 24 | -4.2% | -31.9% |
| Q1 26 | — | 9.7% | ||
| Q4 25 | 0.1% | 15.8% | ||
| Q3 25 | 0.0% | 4.4% | ||
| Q2 25 | 0.0% | 3.0% | ||
| Q1 25 | 0.0% | 9.2% | ||
| Q4 24 | 0.0% | 9.5% | ||
| Q3 24 | 0.0% | 3.1% | ||
| Q2 24 | 0.0% | 5.1% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.50× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
EAF
暂无分部数据
